GRIA2: A Potential Drug Target and Biomarker for GBM (G2891)

Target Name: GRIA2

NCBI ID: G2891

GRIA2

GRIA2: A Potential Drug Target and Biomarker for GBM

Glioblastoma multiforme (GBM) is a type of brain cancer that is often treated with chemotherapy, radiation therapy, and/or surgery. Despite these treatments, the survival rate for GBM patients remains poor, with a five-year survival rate of only around 15%.

One of the main challenges in treating GBM is the development of resistance to therapy, which can lead to a worsening of treatment outcomes. To address this challenge, researchers have been investigating new potential drug targets and biomarkers for GBM.

GRIA2: A Potential Drug Target and Biomarker for GBM

GRIA2 (Glioblastoma Research Association 2) is a protein that is expressed in various tissues and organs, including brain. It has been shown to be involved in the development and progression of GBM.

GRIA2 has been shown to promote the growth and survival of GBM cells in both in vitro and in vivo models. It has also been shown to interact with several other proteins that are involved in the development and progression of GBM, including the transcription factor, NF-kappa-B.

In addition, GRIA2 has been shown to be involved in the regulation of the blood-brain barrier (BBB), which is a barrier that separates the brain from the blood and plays a role in the delivery of drugs to the brain. By regulating the BBB, GRIA2 has been shown to contribute to the development and maintenance of GBM.

GRIA2 is also a potential biomarker for GBM, as its expression has been shown to be associated with the diagnosis and prognosis of GBM.

The Potential clinical Applications of GRIA2 as a Drug Target and Biomarker for GBM

The potential clinical applications of GRIA2 as a drug target and biomarker for GBM are vast.

One of the main potential applications of GRIA2 as a drug target is the treatment of GBM. By inhibiting the activity of GRIA2, researchers could potentially develop new treatments for GBM that are more effective than current treatments. This could lead to a better treatment outcomes for GBM patients.

Another potential application of GRIA2 as a drug target is the development of new biomarkers for GBM. By detecting the expression of GRIA2 in GBM cells, researchers could potentially develop new tests for the diagnosis and prognosis of GBM. This could lead to earlier detection of GBM and better treatment outcomes for patients.

In addition, GRIA2 has also been shown to be involved in the regulation of the BBB, which is a barrier that separates the brain from the blood and plays a role in the delivery of drugs to the brain. By targeting GRIA2, researchers could potentially develop new treatments for GBM that are able to bypass the BBB and reach the brain.

Conclusion

GRIA2 is a protein that is involved in the development and progression of Glioblastoma multiforme (GBM). It has been shown to promote the growth and survival of GBM cells in both in vitro and in vivo models, and to contribute to the regulation of the blood-brain barrier.

As a potential drug target and biomarker for GBM, GRIA2 has the potential to lead to new and more effective treatments for GBM. Further research is needed to fully understand the role of GRIA2 in GBM and to develop new treatments based on this protein.

Protein Name: Glutamate Ionotropic Receptor AMPA Type Subunit 2

Functions: Receptor for glutamate that functions as ligand-gated ion channel in the central nervous system (PubMed:31300657). It plays an important role in excitatory synaptic transmission. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inactive state, characterized by the presence of bound agonist. In the presence of CACNG4 or CACNG7 or CACNG8, shows resensitization which is characterized by a delayed accumulation of current flux upon continued application of glutamate. Through complex formation with NSG1, GRIP1 and STX12 controls the intracellular fate of AMPAR and the endosomal sorting of the GRIA2 subunit toward recycling and membrane targeting (By similarity)

The "GRIA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GRIA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets